As a highly effective and broad-spectrum drug against animal and human parasite, bacterial and fungal infections, nitazoxanide is widely concerned. It is the first and only drug approved by the U.S. drug and Food Administration for the treatment of Cryptosporidium. In vitro studies showed that nitazoxanide had broad-spectrum antibacterial and antiparasitic effects, and could treat infections caused by helminths such as dysentery amoeba, Giardia, Trichomonas vaginalis, protozoa, Campylobacter jejuni, Clostridium difficile, Clostridium perfringens, Helicobacter pylori and other bacteria. It is similar to albendazole and praziquantel in the treatment of Ascaris lumbricoides and Hymenolepis in children.
Manufacturing
